Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia
Ms Inez Jabalpurwala, President and CEO, Brain Canada Foundation
UK-Italy dementia workshop, January 2018 - Nick FoxUKinItaly
The UK Dementia Research Institute (UK DRI) was established with £250 million in joint funding from the MRC, Alzheimer's Society, and Alzheimer's Research UK to accelerate dementia research in the UK. The UK DRI brings together over 300 researchers across 5 centers at universities in Cambridge, Cardiff, Edinburgh, Imperial, Kings College London, and a hub at UCL. It aims to invigorate the therapeutic pipeline for dementias by focusing on innovative discovery science, attracting new talent, and fostering collaboration between research groups through sustained funding, sharing of resources, and an integrated research environment.
David Carr: Maximising the availability and use of research outputs – a funde...NeilStewartCity
The document discusses the Wellcome Trust's position on open access and data sharing. It outlines the Trust's policies promoting open access publishing and data management and sharing. It acknowledges progress in open access compliance but more is needed. New policies strengthen incentives for compliance and require open licensing. The Trust also supports initiatives like eLife and partnerships to build infrastructure for sharing life science data. Challenges remain around cultural, technical and ethical issues, but funders are increasingly working together towards the goals of equitable, ethical and efficient sharing of public health research data.
The document discusses a project by the UK Physical Sciences Subject Centre to develop open educational resources (OER) through engaging communities of practice. [1] It initiated a project called "Skills for Scientists" that involved 19 partners from 17 institutions to produce over 600 credits of OER content across various physical science subjects. [2] Feedback found the project raised awareness of OER benefits and many participants were now more willing to create and share their own OER. [3]
Holly Neill EMRAN presentation - vapn and laeoCCraig138
The Vulnerable Adults' Providers Network (VAPN) is a network for voluntary and community sector organizations that work with vulnerable adults in Nottingham. The VAPN aims to help members better support vulnerable adults, improve their services, and connect groups to commissioning opportunities. The VAPN holds bi-monthly meetings to share information, connect members, and discuss the local commissioning process. It is also connected to other networks in Nottingham to further share information amongst members.
Ass Af Conference Presentation 02 July 2008.Docpowerinbetween
The changing in the world of research communication: from the perspective of people working in information and communication roles and at the supply end of research.
Presentation by Dr. Xola Mati, Chief Operations Officer, Academy of Science of South Africa (ASSAf) at the Locating the Power of the In-between conference July 08
The document discusses green revolving funds (GRFs) which are self-sustaining funds used by institutions to finance energy efficiency upgrades. It notes that over 150 GRFs exist in higher education and other sectors. GRFs provide benefits like alleviating budget pressures, updating buildings, and supporting emissions reductions goals. The Billion Dollar Green Challenge aims to commit $1 billion total to GRFs across institutions, and has already secured commitments of over $125 million from 61 participating organizations. The Green Revolving Investment Tracking System (GRITS) can help institutions track project data to manage their GRFs.
This document summarizes the SOPRANO research project which aims to understand how non-statutory organizations support older people's well-being and resilience. The project will explore relationships between commissioning bodies and third sector organizations, and barriers to coordinated services. Stakeholders include commissioners, voluntary organization managers, staff, volunteers, older people, and carers. Methods include surveys of commissioners, interviews with stakeholders, and systematic reviews of needs assessment tools. The goals are to produce recommendations to improve integration of services around individual needs.
UK-Italy dementia workshop, January 2018 - Nick FoxUKinItaly
The UK Dementia Research Institute (UK DRI) was established with £250 million in joint funding from the MRC, Alzheimer's Society, and Alzheimer's Research UK to accelerate dementia research in the UK. The UK DRI brings together over 300 researchers across 5 centers at universities in Cambridge, Cardiff, Edinburgh, Imperial, Kings College London, and a hub at UCL. It aims to invigorate the therapeutic pipeline for dementias by focusing on innovative discovery science, attracting new talent, and fostering collaboration between research groups through sustained funding, sharing of resources, and an integrated research environment.
David Carr: Maximising the availability and use of research outputs – a funde...NeilStewartCity
The document discusses the Wellcome Trust's position on open access and data sharing. It outlines the Trust's policies promoting open access publishing and data management and sharing. It acknowledges progress in open access compliance but more is needed. New policies strengthen incentives for compliance and require open licensing. The Trust also supports initiatives like eLife and partnerships to build infrastructure for sharing life science data. Challenges remain around cultural, technical and ethical issues, but funders are increasingly working together towards the goals of equitable, ethical and efficient sharing of public health research data.
The document discusses a project by the UK Physical Sciences Subject Centre to develop open educational resources (OER) through engaging communities of practice. [1] It initiated a project called "Skills for Scientists" that involved 19 partners from 17 institutions to produce over 600 credits of OER content across various physical science subjects. [2] Feedback found the project raised awareness of OER benefits and many participants were now more willing to create and share their own OER. [3]
Holly Neill EMRAN presentation - vapn and laeoCCraig138
The Vulnerable Adults' Providers Network (VAPN) is a network for voluntary and community sector organizations that work with vulnerable adults in Nottingham. The VAPN aims to help members better support vulnerable adults, improve their services, and connect groups to commissioning opportunities. The VAPN holds bi-monthly meetings to share information, connect members, and discuss the local commissioning process. It is also connected to other networks in Nottingham to further share information amongst members.
Ass Af Conference Presentation 02 July 2008.Docpowerinbetween
The changing in the world of research communication: from the perspective of people working in information and communication roles and at the supply end of research.
Presentation by Dr. Xola Mati, Chief Operations Officer, Academy of Science of South Africa (ASSAf) at the Locating the Power of the In-between conference July 08
The document discusses green revolving funds (GRFs) which are self-sustaining funds used by institutions to finance energy efficiency upgrades. It notes that over 150 GRFs exist in higher education and other sectors. GRFs provide benefits like alleviating budget pressures, updating buildings, and supporting emissions reductions goals. The Billion Dollar Green Challenge aims to commit $1 billion total to GRFs across institutions, and has already secured commitments of over $125 million from 61 participating organizations. The Green Revolving Investment Tracking System (GRITS) can help institutions track project data to manage their GRFs.
This document summarizes the SOPRANO research project which aims to understand how non-statutory organizations support older people's well-being and resilience. The project will explore relationships between commissioning bodies and third sector organizations, and barriers to coordinated services. Stakeholders include commissioners, voluntary organization managers, staff, volunteers, older people, and carers. Methods include surveys of commissioners, interviews with stakeholders, and systematic reviews of needs assessment tools. The goals are to produce recommendations to improve integration of services around individual needs.
Movers & Shakers: Health and Wellbeing for Older PeopleUniversity of Bath
Presentation by Olga McBarnett for the ESRC Seminar Series on Ageing and Physical Activity - "Community based showcase: Building sustained partnerships and sharing resources"
http://seminars.ecehh.org
The document discusses a workshop on public health and mental health. It provides background information on the voluntary sector's role in public health and improving health in Hertfordshire. Statistics are given on the prevalence of depression and dementia in the area. Projections show the elderly population and those with dementia will increase significantly by 2020. The workshop aims to discuss how the voluntary sector can contribute to public health services, policy development, and tackling health inequalities.
European Chiropractor's Union - 2014 - Dublinjpndresearch
Derick Mitchell, Communications Executive JPND, delivered a JPND presentation during the "A tidal wave of neurodegeneration is coming" session as part of the 2014 meeting of the European Chiropractor's Union
Global Dementia Legacy Event: Raj Long, Senior Regulatory OfficerDepartment of Health
Raj Long presented on regulatory challenges for dementia treatment development and proposed innovative regulatory approaches. Key challenges included the prolonged time required for R&D, uncertainties around classifying and measuring dementia, and regulatory variances between geographies. These factors increase costs and risks for pharmaceutical companies, deterring investment. To address this, Long suggested regulatory designations to expedite review, adaptive development and licensing models, increased international regulator collaboration, incentives for developers, and public-private partnerships to accelerate cure discovery by 2025. Current approaches were deemed insufficient given the high risks and costs of dementia R&D.
Dementia - what can Public Health do to respond to the scope for Prevention? - Olga Cleary
IPH, Open, Conference, Belfast, Northern, Ireland, Dublin, Titanic, October, 2014, Public, Health
Improved lighting can help the UK’s ageing population enjoy their lives, improve their health and avoid some of distressing conditions of old age. Lighting solutions and technologies are often more cost-effective than drug-based treatments. You will see through this presentation how well-designed lighting can lead to improved health and alertness – and how we might push the issue up the health agenda.
Talk by Carl Gardner, CSG Lighting Consultancy Ltd
Mitochondrial DNA (mtDNA) encodes proteins that are essential components of the oxidative phosphorylation (OXPHOS) system located in the inner mitochondrial membrane. Defects in mtDNA or nuclear genes involved in mitochondrial functions can cause a wide range of mitochondrial diseases. MtDNA is maternally inherited and mutations can be transmitted from mother to offspring. Common mitochondrial diseases include Chronic Progressive External Ophthalmoplegia (CPEO), Kearns-Sayre Syndrome (KSS), MELAS, MERRF, and Leber Hereditary Optic Neuropathy (LHON). These diseases have varying clinical features depending on the mutation and often affect the brain, muscles, and eyes.
The document discusses dementia, including that the development of dementia is increasing rapidly as the population ages. It notes that the individual chose to research dementia because it is becoming more common and they want to work in healthcare. The document then provides an overview of dementia that will be discussed in more detail, including causes, symptoms, diagnosis and treatment. It states that dementia is not one disease but a collection of symptoms caused by various disorders.
The document provides an impact report and summary of activities from Brain Tumour Foundation of Canada in 2014. Key points include:
- Over 11,000 connections were made with patients, families, and healthcare professionals to provide support and resources.
- $1.09 million was invested in 17 research projects across Canada to advance the understanding and treatment of brain tumors.
- A formal presence was established in Quebec, and support programs like BrainWAVE expanded to Alberta to serve more patients nationally.
ere we continue with the remaining concept of crowdfunding. As stated crowd-funding is gearing significance in the field of clinical research or medical research in general.
Founded in 2016, the Glioblastoma Foundation. stands as the premier nonprofit organization in the United States, committed to battling organization of a terminal stage 4 brain tumor. Located at 2451 Croasdaile Farm Parkway, Suite 109 in Durham, NC, the foundation has a national presence, supporting patients from coast to coast while also financing groundbreaking research for a cure.
The document discusses the Intensive Care Foundation (ICF), which coordinates over 70% of UK intensive care research. The ICF was established 10 years ago by the Intensive Care Society (ICS) to promote critical care study and research. While the ICS currently provides most funding, the ICF's long-term focus is becoming self-funded through diverse income streams like other medical charities. The ICF has established an important role in the critical care community by funding quality research projects through a competitive peer review process.
The S.T.A.R. Initiative Knowledge Exchange and Engagement Program Touring Exh...Regina Greer-Smith LFACHE
The Knowledge Exchange and Engagement Exhibit is a year-long traveling exhibit to engage patients, researchers, caregivers, and stakeholders to foster collaboration and discussion of the benefits of research for better health outcomes and shared-decision making
Fight Colorectal Cancer advocates for increased funding and awareness for colorectal cancer research and treatment. They educate patients and caregivers and push for policy changes to advance research. Though they accept funding from various sources, their programs are developed for those affected by colorectal cancer. Advocacy has led to greater public research funding and clinical trials for colorectal cancer compared to other cancers, but more work remains as mortality rates remain high.
The document provides information about the Kidney Foundation of Canada Windsor & District Chapter. It discusses the chapter's vision, mission, goals, history since the 1960s, programs, advocacy, fundraising events, volunteer opportunities and operations in the Windsor region.
The document outlines Canada's Rare Disease Strategy, which aims to improve the lives of those affected by rare diseases through 5 key goals: 1) improving early detection and prevention, 2) providing timely, equitable care, 3) enhancing community support, 4) providing sustainable access to therapies, and 5) promoting innovative research. Rare diseases affect over 2.8 million Canadians and early detection is challenging, with many receiving misdiagnoses or facing long wait times. The strategy seeks to establish newborn screening, genetic testing guidelines, clinical expertise centers, and a national rare disease drug program to help ensure Canadians have consistent access to treatments.
The document summarizes the mission and activities of the UK Medical Research Council (MRC). The MRC aims to support high-quality health research, train researchers, and disseminate knowledge to improve lives and economic competitiveness in the UK and worldwide. It focuses on areas like neuroscience, mental health, infections, aging, and uses approaches such as clinical trials, epidemiology, and stem cell and regenerative medicine research.
The document introduces the All of Us Research Program, which aims to collect health data from one million Americans to advance precision medicine research. It was announced by President Obama in 2015. The program receives funding from the federal government and private partners. It collects various types of health data from participants through surveys, health records, samples, and devices. The data is stored and shared securely while protecting privacy. The goal is to generate new medical discoveries and more personalized healthcare through collaboration between researchers and participants.
EuroBioForum 2013 - Day 1 | Etienne RicherEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Canada:
Personalised Medicine: A Canadian Collaborative Perspective'
Dr Étienne Richer, Assistant Director at CIHR Institute of Genetics
=======================================
http://www.eurobioforum.eu
Presentation by Clare Woods, Business Development Manager for MedTech, NIHR at Excel in Health: developing your innovation for business on Tuesday 12 March 2019 at the Innovation Centre, Daresbury.
Movers & Shakers: Health and Wellbeing for Older PeopleUniversity of Bath
Presentation by Olga McBarnett for the ESRC Seminar Series on Ageing and Physical Activity - "Community based showcase: Building sustained partnerships and sharing resources"
http://seminars.ecehh.org
The document discusses a workshop on public health and mental health. It provides background information on the voluntary sector's role in public health and improving health in Hertfordshire. Statistics are given on the prevalence of depression and dementia in the area. Projections show the elderly population and those with dementia will increase significantly by 2020. The workshop aims to discuss how the voluntary sector can contribute to public health services, policy development, and tackling health inequalities.
European Chiropractor's Union - 2014 - Dublinjpndresearch
Derick Mitchell, Communications Executive JPND, delivered a JPND presentation during the "A tidal wave of neurodegeneration is coming" session as part of the 2014 meeting of the European Chiropractor's Union
Global Dementia Legacy Event: Raj Long, Senior Regulatory OfficerDepartment of Health
Raj Long presented on regulatory challenges for dementia treatment development and proposed innovative regulatory approaches. Key challenges included the prolonged time required for R&D, uncertainties around classifying and measuring dementia, and regulatory variances between geographies. These factors increase costs and risks for pharmaceutical companies, deterring investment. To address this, Long suggested regulatory designations to expedite review, adaptive development and licensing models, increased international regulator collaboration, incentives for developers, and public-private partnerships to accelerate cure discovery by 2025. Current approaches were deemed insufficient given the high risks and costs of dementia R&D.
Dementia - what can Public Health do to respond to the scope for Prevention? - Olga Cleary
IPH, Open, Conference, Belfast, Northern, Ireland, Dublin, Titanic, October, 2014, Public, Health
Improved lighting can help the UK’s ageing population enjoy their lives, improve their health and avoid some of distressing conditions of old age. Lighting solutions and technologies are often more cost-effective than drug-based treatments. You will see through this presentation how well-designed lighting can lead to improved health and alertness – and how we might push the issue up the health agenda.
Talk by Carl Gardner, CSG Lighting Consultancy Ltd
Mitochondrial DNA (mtDNA) encodes proteins that are essential components of the oxidative phosphorylation (OXPHOS) system located in the inner mitochondrial membrane. Defects in mtDNA or nuclear genes involved in mitochondrial functions can cause a wide range of mitochondrial diseases. MtDNA is maternally inherited and mutations can be transmitted from mother to offspring. Common mitochondrial diseases include Chronic Progressive External Ophthalmoplegia (CPEO), Kearns-Sayre Syndrome (KSS), MELAS, MERRF, and Leber Hereditary Optic Neuropathy (LHON). These diseases have varying clinical features depending on the mutation and often affect the brain, muscles, and eyes.
The document discusses dementia, including that the development of dementia is increasing rapidly as the population ages. It notes that the individual chose to research dementia because it is becoming more common and they want to work in healthcare. The document then provides an overview of dementia that will be discussed in more detail, including causes, symptoms, diagnosis and treatment. It states that dementia is not one disease but a collection of symptoms caused by various disorders.
The document provides an impact report and summary of activities from Brain Tumour Foundation of Canada in 2014. Key points include:
- Over 11,000 connections were made with patients, families, and healthcare professionals to provide support and resources.
- $1.09 million was invested in 17 research projects across Canada to advance the understanding and treatment of brain tumors.
- A formal presence was established in Quebec, and support programs like BrainWAVE expanded to Alberta to serve more patients nationally.
ere we continue with the remaining concept of crowdfunding. As stated crowd-funding is gearing significance in the field of clinical research or medical research in general.
Founded in 2016, the Glioblastoma Foundation. stands as the premier nonprofit organization in the United States, committed to battling organization of a terminal stage 4 brain tumor. Located at 2451 Croasdaile Farm Parkway, Suite 109 in Durham, NC, the foundation has a national presence, supporting patients from coast to coast while also financing groundbreaking research for a cure.
The document discusses the Intensive Care Foundation (ICF), which coordinates over 70% of UK intensive care research. The ICF was established 10 years ago by the Intensive Care Society (ICS) to promote critical care study and research. While the ICS currently provides most funding, the ICF's long-term focus is becoming self-funded through diverse income streams like other medical charities. The ICF has established an important role in the critical care community by funding quality research projects through a competitive peer review process.
The S.T.A.R. Initiative Knowledge Exchange and Engagement Program Touring Exh...Regina Greer-Smith LFACHE
The Knowledge Exchange and Engagement Exhibit is a year-long traveling exhibit to engage patients, researchers, caregivers, and stakeholders to foster collaboration and discussion of the benefits of research for better health outcomes and shared-decision making
Fight Colorectal Cancer advocates for increased funding and awareness for colorectal cancer research and treatment. They educate patients and caregivers and push for policy changes to advance research. Though they accept funding from various sources, their programs are developed for those affected by colorectal cancer. Advocacy has led to greater public research funding and clinical trials for colorectal cancer compared to other cancers, but more work remains as mortality rates remain high.
The document provides information about the Kidney Foundation of Canada Windsor & District Chapter. It discusses the chapter's vision, mission, goals, history since the 1960s, programs, advocacy, fundraising events, volunteer opportunities and operations in the Windsor region.
The document outlines Canada's Rare Disease Strategy, which aims to improve the lives of those affected by rare diseases through 5 key goals: 1) improving early detection and prevention, 2) providing timely, equitable care, 3) enhancing community support, 4) providing sustainable access to therapies, and 5) promoting innovative research. Rare diseases affect over 2.8 million Canadians and early detection is challenging, with many receiving misdiagnoses or facing long wait times. The strategy seeks to establish newborn screening, genetic testing guidelines, clinical expertise centers, and a national rare disease drug program to help ensure Canadians have consistent access to treatments.
The document summarizes the mission and activities of the UK Medical Research Council (MRC). The MRC aims to support high-quality health research, train researchers, and disseminate knowledge to improve lives and economic competitiveness in the UK and worldwide. It focuses on areas like neuroscience, mental health, infections, aging, and uses approaches such as clinical trials, epidemiology, and stem cell and regenerative medicine research.
The document introduces the All of Us Research Program, which aims to collect health data from one million Americans to advance precision medicine research. It was announced by President Obama in 2015. The program receives funding from the federal government and private partners. It collects various types of health data from participants through surveys, health records, samples, and devices. The data is stored and shared securely while protecting privacy. The goal is to generate new medical discoveries and more personalized healthcare through collaboration between researchers and participants.
EuroBioForum 2013 - Day 1 | Etienne RicherEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Canada:
Personalised Medicine: A Canadian Collaborative Perspective'
Dr Étienne Richer, Assistant Director at CIHR Institute of Genetics
=======================================
http://www.eurobioforum.eu
Presentation by Clare Woods, Business Development Manager for MedTech, NIHR at Excel in Health: developing your innovation for business on Tuesday 12 March 2019 at the Innovation Centre, Daresbury.
Crowdfunding for medical research picks up pace.pdfJichaoChen2
Crowdfunding for medical research is gaining popularity as a way to raise funds for projects that may not receive traditional sources of funding. Several researchers have turned to crowdfunding sites with success, raising thousands of dollars from public donations for projects. However, some concerns remain that only "sexy" projects about animals may attract funds, and that peer review is still needed to vet projects. As government research funding declines, crowdfunding may continue growing as a way for young researchers to obtain seed funding, but growing the infrastructure and vetting process will be important for it to reach larger scales of funding.
The document discusses the UK government's dementia policy and progress made towards their goals. Key points:
- Over 670,000 people in England have dementia, a number that will double in 30 years, costing £19 billion annually.
- Goals include increasing diagnosis rates to two-thirds by 2015 and making communities more dementia-friendly.
- Progress includes training over 2,000 volunteers, 50 dementia-friendly cities, and £22 million for research projects.
- Next steps focus on greater collaboration, engaging more communities, and influencing wider health systems.
Presentation ice child brain foundation - lbs adf 10.06.2011.ppt [enregistr...ADionisi
The Child Brain Foundation aims to establish the first international research foundation focused on child neurosciences. It will consolidate current expertise at Hopital Robert Debre, one of the largest children's hospitals in France, and explore new areas of neuroscience research. The Foundation will fund a range of research activities, from basic to clinical studies, focusing on protection and development of the child's brain. It will take an innovative approach through the use of technologies like tablets, social networks, and a collaborative platform to share knowledge between medical professionals, families, and partners. The goal is to transform child healthcare by preventing and curing neurological diseases while also connecting medical care to educational development.
Community Nursing Research Strategy Masterclass
13th September 2013
The WSPCR was requested to organise a research masterclass for the Directors of Nursing from all the Welsh Health Boards on Friday 11th Sept. It was funded by the Health Minister and attended by the CNO. It also included the Head of the NISCHR and the manager of AHSC. The masterclass included the presentation of the Welsh Community Nurse Research Strategy which aims to raise the quality and quantity of research in Community Nursing in Wales. The workshop also generated further areas for research activity/priority.
http://www.wspcr.ac.uk/crns-masterclass-sep-2013.php
The ICDDRB is one of the world's leading global health research institutes based in Dhaka, Bangladesh. It is committed to solving public health problems in low- and middle-income countries through scientific research, including laboratory, clinical, and epidemiological research. For over 50 years, it has conducted high-quality research and promoted evidence-based interventions to improve health, initially focusing on diarrheal diseases and now studying multiple infectious diseases and health systems. Its work has significantly impacted health policies and practices globally.
MICYRN is a Canadian non-profit organization established in 2011 to reduce barriers and duplication of effort in multi-jurisdictional pediatric research, particularly for rare diseases. Rare diseases affect over 2.7 million Canadians but each affects fewer than 2000 individuals. MICYRN works to improve diagnosis of rare diseases and develop new therapies through national research networks and collaborating in international research initiatives. MICYRN also supports patient registries and clinical trials infrastructure to study rare diseases and determine drug safety and effectiveness in children through its research informatics platform and partnerships with health organizations and industry.
PwC is a global professional services firm that provides audit, tax, and consulting services. It has established a Personalized Medicine practice to help clients address key healthcare trends and advance personalized healthcare. PwC has worked on various personalized medicine initiatives including establishing research institutes and facilitating strategic partnerships between organizations. Information technology and diagnostics will be important foundations supporting the development of personalized medicine.
Similar to Global Dementia Legacy Event: Ms Inez Jabalpurwala, President and CEO, Brain Canada Foundation (20)
No voice unheard, no right ignored: consultation for people with learning dis...Department of Health
The document outlines proposals to strengthen the rights of people with mental health needs, learning disabilities, and autism in the UK. It discusses 5 key areas for reform: 1) the right to independent living and community inclusion, 2) the right to have one's wishes heard and decisions challenged, 3) rights under the Mental Health Act, 4) the right to control one's own support through personal budgets, and 5) improved coordination between health and social services. The consultation seeks public input on these proposals to ensure laws and policies fully respect the rights of those with mental health conditions or disabilities.
Creating digital tools for mental health and employment support: the discover...Department of Health
This report maps out the needs of potential users of an online mental health and work assessment and support service, suggests key user groups and presents a set of design principles for any a potential future service.
Creating digital tools for mental wellbeing and employment support: pre-alpha...Department of Health
This slide-deck reports on the second phase user research and testing. It presents refined design briefs that can be used to inform future alpha stages and design of a future service. These are themed according to the three core user groups identified in the first phase:
(i) finding work
(ii) in and out of work
(iii) managing work.
Further information on:
- user testing details
- mock-ups of potential digital tools for people finding work
- mock-ups of potential digital tools for people moving in and out of work
- mock-ups of potential digital tools for people managing work
Global Dementia Legacy Event: Canada & France: Dr Etienne Hirsch & Dr Yves Jo...Department of Health
Session Five: The next goal – towards Canada, France, Japan and the United States.
Canada & France: Dr Etienne Hirsch, Director, Institute for Neurosciences, Cognitive sciences, Neurology and Psychiatry at INSERM and the French alliance for life and health science Aviesan & Dr Yves Joanette CIHR, Scientific Director, Canadian Institutes of Health Research (CIHR), Institute of Aging & World Dementia Council Member
Feature presentation - The economic case for action
Professor Martin Knapp, Director, Health &
Personal Social Services Research Unit, London School of Economics & Kings College London
Session Four: Exploring the financial mechanisms that can be harnessed to increase investment in
dementia.
Professor Andrew Lo, MIT Sloan Professor of Finance
Session Four: Exploring the financial mechanisms that can be harnessed to increase investment in
dementia.
Mr. George Vradenburg, Convenor, The Global CEO Initiative on Alzheimer's and Chairman of USAgainstAlzheimer’s & World Dementia Council Member
Marc Wortman, Executive Director, Alzheimer’s Disease International (ADI) Department of Health
Session Three: To explore ways in which we can increase investment in innovation. Part 2 presents a case study of innovation across the globe and the need to continue global collaboration
Marc Wortman, Executive Director, Alzheimer’s Disease International (ADI)
Session Three: To explore ways in which we can increase investment in innovation. Part 2 presents a case study of innovation across the globe and the need to continue global collaboration
DY Suharya, Executive Director of Alzheimer's Indonesia
The International AD Research Funder Consortium (IADRFC) aims to foster collaboration and data sharing between Alzheimer's disease research organizations through developing partnerships, standard templates, and influencing the international research agenda. The Global Alzheimer's Association Interactive Network (GAAIN) is a collaborative effort to provide researchers worldwide access to a vast repository of Alzheimer's research data by establishing a central data infrastructure and engaging data partners. GAAIN will transform heterogeneous local data into a common data model and terminology to allow integrated analysis across datasets.
Session 3: To explore ways in which we can increase investment in innovation. In part 1 panellists will highlight ways in which they are seeking to tackle barriers and find solutions, including through big data, patient involvement in clinical trials and social investment.
Mr. Stephen Johnston, Co-Founder, Aging2.0 & Partner, Generator Ventures
Session 3: To explore ways in which we can increase investment in innovation. In part 1 panellists will highlight ways in which they are seeking to tackle barriers and find solutions, including through big data, patient involvement in clinical trials and social investment.
Mr. Tom Wright CBE, Group CEO, Age UK
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia
Dr Neil Buckholtz , Director of Neuroscience, the National Institute on Aging (NIA), National Institutes of Health (NIH)
The document discusses the need for global collaboration to conquer Alzheimer's disease. It notes that knowing is not enough and we must apply what we know. It advocates changing the dialogue around Alzheimer's to focus on the disease rather than just the patient. Key needs for "disease interception" are identified, including increased investment in basic science, incentivizing innovators, improving diagnostic tools and biomarkers, establishing clinical trial registries, building translational infrastructure between registries and trial-ready cohorts, using relevant outcomes measures, and creating a synchronized regulatory environment. The presentation promotes the Global Alzheimer's Platform as a way to foster data sharing, collaboration, and building a "global connectome" to accelerate progress on Alzheimer's.
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia.
Elisabetta Vaudano DVM PhD, Coordinator Scientific Pillar, Principal Scientific Manager, Innovative Medicines Initiative
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia.
John Ryan, Acting Director of the European Commission Public Health Directorate
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia.
Professor Lefkos Middleton, Professor of Neurology, Neuroepidemiology and Ageing Research at School of Public Health, Imperial College London
Dr Shekhar Saxena, Director of the Department of Mental Health and Substance Abuse at World Health Organization (WHO) & Technical Advisor to the World Dementia Council
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Global Dementia Legacy Event: Ms Inez Jabalpurwala, President and CEO, Brain Canada Foundation
1. Brain Canada
2014 Global Dementia Legacy Event
London, UK, June 19th, 2014
Inez Jabalpurwala, President & CEO
2. Vision: To understand the brain, in health and illness, to improve lives and
achieve societal impact.
Mission: Brain Canada is achieving its vision by:
Increasing the scale and scope of funding to accelerate the pace of
Canadian brain research;
Creating a collective commitment to brain research across the public,
private and voluntary sectors;
Delivering transformative, original and outstanding research programs.
Brain Canada
3. An independent Board of Directors with distinguished members drawn from
the business, science, and academic communities
Chair, Rupert Duchesne, Group Chief Executive, AIMIA Inc.
Honourary Chair, Hon. Michael H. Wilson
Ongoing consultation with the research community in Canada and
internationally and other stakeholders
Research Policy Committee and Science Advisory Forum, with Canadian and
international members (to replace Science Advisory Council)
Chair, Brian MacVicar, University of British Columbia
Stakeholder consultations
Strategic planning process
Brain Canada – joining business and
science leadership
4. On June 6, 2011, the Canadian government allocated up to $100 million in
new funding over six years to establish the Canada Brain Research Fund “to
support the very best Canadian neuroscience,” to be matched by $100 million
in private and non-governmental sources, with funding stewarded by Brain
Canada
The Canada Brain Research Fund (CBRF) is a partnership between Brain
Canada, the Government of Canada, and all those who share the commitment
to advancing brain research and brain health; the Fund is intended to
stimulate increased awareness and investment in brain research
The Canada Brain Research Fund
5. The Canada Brain Research Fund
A Public-Private Partnership to Support Canada’s World Class Brain Research
6. CBRF - expected outcomes
A substantial increase in private investment in brain research in Canada
An increase in the number of multidisciplinary, networked researchers
and research projects in universities and academic health centres
Training for the next generation of researchers
A stronger neuroscience community through increased partnerships
and collaborations, leading to
A reduced individual and societal burden of brain disease
7. Highlights since launch of CBRF in May 2012
Closing on $45 million raised. These funds are being matched on a 1:1 basis by
the Government of Canada to reach $90 million
Includes largest private commitment to support Alzheimer prevention
research - $25 million from Chagnon Family
Includes largest private donation to support neurodevelopmental research
(with a focus on Autism Spectrum Disorder and Fragile X syndrome) –
$7.5 million from the Azrieli Foundation
$35.5 million already allocated – this is new funding for brain research
9. Brain Canada’s support of research on
Alzheimer’s disease and dementia
$25 million – partnership with the Chagnon Family for research on prevention
interventions for Alzheimer Disease and Related Disorders
$7.5 million – partnership in British Columbia to support projects focused on
Alzheimer Disease research led by Principal Investigators in British Columbia
$5.6 million – partnership with funding organizations in Alberta to support
project(s) studying healthy brain aging and dementia in Alberta
$1.5 million – partnership with The W. Garfield Weston Foundation and Krembil
Foundation for early detection methods for brain amyloid in neurodegeneration
~$8 million – partnerships with universities, hospitals for support of national and
regional infrastructure (under review)
10. What we have learned
At more than $40 million (funds already allocated + donor and partner
commitments), largest allocation from CBRF is expected to support
Alzheimer’s disease/dementia research
Public-private partnership means harnessing the power of philanthropy to
direct Government funding
Patient/family/donor voice key to size of investment and major focus on
prevention
11. What’s next
A more strategic approach:
What is happening around the world—from silos to collaborations—risk
of another type of fragmentation
Where are the gaps and opportunities for a coordinated strategy for
research AND investment which integrates the patient/family/donor
voice; what outcomes do we want to achieve
How can Canada connect to this